EG 427
EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
EG 427
Industry:
Biotechnology Genetics Therapeutics
Founded:
2019-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.eg427.com
Total Employee:
1+
Status:
Active
Total Funding:
12 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail
Similar Organizations
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Current Advisors List
Current Employees Featured
Founder
Investors List
Stephane Boissel
Stephane Boissel investment in Series A - EG 427
David Lamond
David Lamond investment in Series A - EG 427
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-14 | EG 427 appoints Grzegorz Sarek, Ph.D., as Vice President of Research |
Official Site Inspections
http://www.eg427.com
- Host name: 195-15-240-42.pub1.etik-cloud.com
- IP address: 195.15.240.42
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "EG 427"
PINPOINT DNA MEDICINES FOR CHRONIC DISEASES
Unlocking the full potential of non-replicative Herpes Simplex Virus 1 (nrHSV-1) vectors as a powerful gene therapy platform. This allows for the expression of large genes under the control of sophisticated regulatory elements, in a safe …See details»
About us - eg427.com
Company. EG 427 is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy. Our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) …See details»
EG 427 - Crunchbase Company Profile & Funding
EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.See details»
EG 427 Company Profile 2024: Valuation, Funding & Investors
EG 427 General Information Description. Developer of a pinpoint gene therapy intended to cure spinal cord injury-related disorders. The company develops HSV-1-based vectors by exploiting …See details»
EG 427 - LinkedIn
EG 427 | 1,560 followers on LinkedIn. Pinpoint Gene Therapy | At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint …See details»
EG 427 Appoints Don Haut, Ph.D as Chief Business Officer and …
Dec 14, 2023 427 is at a pivotal juncture, transitioning from a pre-clinical to a clinical stage organization,” says Philippe Chambon, Chief Executive Officer at EG 427. Most recently, Dr. …See details»
EG 427 (FR, Pinpoint Gene Therapy) - Life-Sciences-Europe.com
BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) EuropaBio aisbl – the European Association of Bioindustries; BioIndustry Association (BIA) …See details»
EG 427 Company Information - Funding, Investors, and More
Website: https://eg427.com; Business model: b2c Company size: 11 - 51 employees Headquarters: Paris, France Founded: 2019 Similar startup. Mistral AI Seedtable Score 78. …See details»
EG 427 announces final Series A closing, achieving €18 million in …
Paris, France, 13 July, 2023 – EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, announces today the final closing of a Series A financing. …See details»
EG 427 - Profile
EG 427 is a biotechnology company leading the development of pinpoint DNA medicine solutions. It has developed a non-replicative Herpes Simplex Virus type 1 (nrHSV-1) based vector …See details»
EG 427 announces final Series A closing, achieving €18
Jul 13, 2023 [email protected] : Investors Chris Maggos Cohesion Bureau [email protected] +41 79 367 62 54 : Media contacts: United States Selina …See details»
EG 427 announces €12 million Series A financing to advance its …
Mar 1, 2021 Contacts:CompanyPhilippe Chambon, M.D., Ph.D.EG [email protected] Media USRyo Imai / Robert Flamm, Ph.D.Burns McClellan, Inc.212 …See details»
EG 427 announces issuance of the first 2 patents for its
Apr 11, 2023 EG427 has developed a unique, non-replicative Herpes Simplex Virus type 1 (nrHSV-1) based vector platform. ... For more information, visit the organization’s website at ...See details»
EG 427 announces final Series A closing, achieving 18 million in …
Jul 13, 2023 www.EG427.com never used since it leads to other impairments. This surgical technique severs dorsal nerve roots in the spinal cord and is not selective for bladder sensory …See details»
EG 427 announces €12 million Series A financing to advance
Mar 1, 2021 [email protected]. Media . US Ryo Imai / Robert Flamm, Ph.D. Burns McClellan, Inc. 212-213-0006 ext. 315 / 364 [email protected] / ...See details»
More documents for EG 427 (FR, Pinpoint Gene Therapy)
David Lamond and Stephane Boissel join the company’s board of Directors EG 427, a biotechnology company developing pinpoint gene therapy, today announced the closing of a …See details»
EG 247 - Products, Competitors, Financials, Employees, …
EG 247. Frequently Asked Questions (FAQ). When was EG 247 founded? EG 247 was founded in 2019. Where is EG 247's headquarters? EG 247's headquarters is located at 29 rue du …See details»
News - eg427.com
EG427 will be presenting at Bio-Europe Spring 2022 2022-11-04. Attend our presentation to know more about the company. Looking forward to e-meet you there! Meet us at Cell Gene Med …See details»
20230403 PR EG 427 EPO Patent grant Vf US
Apr 11, 2023 www.EG427.com Contacts: Company Philippe Chambon, M.D., Ph.D. EG 427 Founder and CEO US: 415-533-9359 FR: +33 7 70 02 22 08 [email protected] Media US …See details»
First gene therapy for prevalent pathologies in neurology
Jun 24, 2024 First gene therapy for prevalent pathologies in neurology receives FDA IND clearance - EG 427 initiating first-in-human clinical study. June 24, 2024 02:00 ET | Source: …See details»